Systemic Lupus Erythematosus Management in Pregnancy

Area of Science:

• Reproductive immunology
• Maternal-fetal medicine
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) significantly impacts women of reproductive age.
• Pregnancy in SLE patients carries risks of disease flares and adverse maternal-fetal outcomes.
• Specific autoantibodies (antiphospholipid, anti-Ro/SSA, anti-La/SSB) confer unique risks during pregnancy.

Purpose of the Study:

• To outline family planning considerations for women with SLE.
• To review pregnancy risks associated with SLE and specific autoantibodies.
• To provide guidance on medication management for SLE patients planning pregnancy.

Main Methods:

• Literature review of SLE in pregnancy and medication safety.
• Analysis of risks associated with SLE disease activity and autoantibodies.
• Recommendations for preconception counseling and management during pregnancy.

Main Results:

• SLE flares during pregnancy can increase risks of fetal loss, pre-eclampsia, preterm birth, and fetal growth restriction.
• Antiphospholipid antibodies are linked to thrombosis and fetal loss.
• Anti-Ro/SSA and anti-La/SSB antibodies pose risks for congenital heart block and neonatal lupus.
• Hydroxychloroquine is recommended for all SLE patients; aspirin may reduce pre-eclampsia risk.
• Certain immunosuppressants (azathioprine, tacrolimus, cyclosporine) and biologics (rituximab, belimumab, abatacept) are compatible with pregnancy/lactation, while others (MMF, methotrexate, leflunomide, cyclophosphamide) are not.

Conclusions:

• Preconception disease control and use of pregnancy-compatible medications are crucial for favorable outcomes in SLE pregnancies.
• Continuous monitoring and tailored medication strategies are essential throughout pregnancy for SLE patients.
• Informed family planning and medication management optimize maternal and fetal health in women with SLE.